Liquid biopsy for precision oncology is a non-invasive diagnostic tool that analyzes circulating tumor DNA (ctDNA) in blood to detect, monitor, and guide the treatment of cancer.
Traditional biopsy methods are invasive and limited in scope; liquid biopsies offer a non-invasive alternative that can be repeated over time to monitor cancer evolution and response to therapy without the need for additional tissue sampling.
The technology involves collecting a small blood sample, isolating ctDNA fragments, and using advanced sequencing and AI algorithms to analyze these genetic materials for mutations associated with specific cancers. This process provides real-time insights into disease progression, enabling personalized treatment strategies.
Manufacturing involves developing high-throughput sequencing platforms, integrating AI algorithms for data analysis, and ensuring clinical validation through rigorous testing in various stages of cancer treatment.
The build process includes sample collection, ctDNA isolation, next-generation sequencing (NGS) or targeted sequencing, bioinformatics processing using machine learning models to identify relevant mutations, and integration with healthcare systems for clinical application.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.